MCA reclassification
This article was originally published in The Tan Sheet
Executive Summary
First two products to be considered under Medicines Control Agency's new drug reclassification system are J&J Consumer Pharmaceuticals' Nizoral Dandruff Shampoo 2% (ketoconazole) and Pharmacia's Regaine Regular Strength (minoxidil 2%). Firms have applied to switch legal status from "Pharmacy" to "General Sale List," MCA says. J&J's Nizoral switched from Rx to pharmacy status in 1996; indications will be for "prevention and treatment of dandruff only," UK agency says. Pharmacia's Regaine will have "improved information on the pack, label and leaflet," as well as dedicated hot line, Web site. New reclassification strategy went into effect April 1 (1"The Tan Sheet" May 6, 2002, p. 4)...
You may also be interested in...
UK Drug Reclassification System May Double OTC Switches – Health Minister
The British government expects its new drug reclassification system to potentially double the number of medicines that switch from prescription to non-Rx status
US Election 2020: Device Firms Spending Twice As Much On Biden Than On Trump
Just five weeks before the US election, a Medtech Insight analysis shows medical device companies are spending more on Democrat Joe Biden’s campaign than on Republican Donald Trump’s.
Orphazyme Raises Funds, Approaching Markets With Novel Niemann-Pick Therapy
Denmark’s Orphazyme has raised more funds to market its lead product, the heat shock protein amplifier, arimoclomol, in the US and Europe, and to evaluate the compound for other lysosomal storage and neurodegenerative disorders.
Need a specific report? 1000+ reports available Buy Reports
Register for our free email digests: